Baillif, S.; Staccini, P.; Weber, M.; Delyfer, M.-N.; Le Mer, Y.; Gualino, V.; Collot, L.; Merite, P.-Y.; Creuzot-Garcher, C.; Kodjikian, L.;
et al. Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant. Pharmaceutics 2022, 14, 2391.
https://doi.org/10.3390/pharmaceutics14112391
AMA Style
Baillif S, Staccini P, Weber M, Delyfer M-N, Le Mer Y, Gualino V, Collot L, Merite P-Y, Creuzot-Garcher C, Kodjikian L,
et al. Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant. Pharmaceutics. 2022; 14(11):2391.
https://doi.org/10.3390/pharmaceutics14112391
Chicago/Turabian Style
Baillif, Stéphanie, Pascal Staccini, Michel Weber, Marie-Noëlle Delyfer, Yannick Le Mer, Vincent Gualino, Laurence Collot, Pierre-Yves Merite, Catherine Creuzot-Garcher, Laurent Kodjikian,
and et al. 2022. "Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant" Pharmaceutics 14, no. 11: 2391.
https://doi.org/10.3390/pharmaceutics14112391
APA Style
Baillif, S., Staccini, P., Weber, M., Delyfer, M.-N., Le Mer, Y., Gualino, V., Collot, L., Merite, P.-Y., Creuzot-Garcher, C., Kodjikian, L., & Massin, P.
(2022). Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant. Pharmaceutics, 14(11), 2391.
https://doi.org/10.3390/pharmaceutics14112391
